Help move asthma care forward

Key Inclusion/Exclusion Criteria for Asthma Protocol Phase 2a

Inclusion Criteria

• Able to read, understand, and sign an informed consent form before any study procedures.
• Male or female adults aged 18 to 75 years with a physician diagnosis of moderate to severe asthma for at least 12 months.
• Receiving stable treatment with an inhaled corticosteroid (ICS) plus a long-acting beta₂-agonist (LABA) for at least 2 months before screening.
• Pre-bronchodilator FEV₁ between 50% and 80% of predicted normal at screening and baseline.
• Demonstrated bronchodilator reversibility, defined as ≥12% and ≥200 mL improvement in FEV₁ (or ≥20% increase in peak expiratory flow) after short-acting bronchodilator use.
• ACQ-5 score ≥1.25 and ≤3.0 at screening and baseline.
• History of at least one asthma exacerbation in the past 12 months requiring systemic corticosteroids or hospitalization/emergency care.

Exclusion Criteria

• Had a moderate or severe asthma exacerbation within 4 weeks before screening.
• Have a history of life-threatening asthma, including intubation or respiratory arrest.
• Have any other significant pulmonary disease (e.g., COPD, bronchiectasis, pulmonary fibrosis, cystic fibrosis, tuberculosis, lung cancer, or eosinophilic syndromes).
• Had bronchial thermoplasty within 2 years before screening.
• Used biologic therapies for asthma (e.g., benralizumab, mepolizumab, reslizumab, omalizumab, dupilumab, or tezepelumab) within 6 months or 5 half-lives prior to baseline.
• Require immunosuppressive medications or frequent systemic corticosteroids (more than 3 courses in the past 6 months).
• Are current smokers or former smokers with >10 pack-year history or who quit within 6 months before screening.
• Have uncontrolled hypertension (systolic ≥160 mmHg or diastolic >95 mmHg).
• Have significant hepatic impairment or any other condition that, in the investigator's opinion, would interfere with study participation or interpretation of results.